Interpreting Ganciclovir Plasma Concentrations to Inform Dosing and Therapeutic Drug Monitoring in (Preterm) Infants With Cytomegalovirus

View at publisher Summarise with VIRAT
Authors: Tom G. Jacobs, Anne‐Grete Märtson
Cited by: 0
References: 10

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

To The Editor—We read the paper by Acosta et al with great interest [1]. Their pharmacokinetic data on ganciclovir in extremely premature infants are essential for optimizing dosing in this vulnerable population. The study shows lower ganciclovir clearance in preterm compared to term neonates, consistent with a previous study showing increased ganciclovir exposure in preterm infants receiving standard term infant-based ganciclovir (6 mg/kg) or valganciclovir (16 mg/kg) doses [2]. As ganciclovir is cleared renally, both gestational (GA) and postnatal age (PNA) strongly influence clearance. Reduced renal function at birth and delayed maturation in infants with lower GA result in prolonged ganciclovir half-life and increased exposure at equivalent mg/kg dose [3]. Thus, preterm infants require lower mg/kg doses compared to term infants to achieve similar ganciclovir exposure. In line with this, Acosta et al suggest a universal ganciclovir starting dose of 5 mg/kg regardless of GA or PNA. However, this pragmatic approach could lead to overdosing for the extreme subpopulations of preterm infants, especially in settings where therapeutic drug monitoring (TDM) is unavailable. Using serum creatinine (Scr) combined with body weight to estimate renal function, as suggested by Acosta et al, could help to optimize ganciclovir dosing. However, Scr can be unreliable in preterm infants during the first few days or weeks of life because it is primarily reflective of maternal Scr and because of low muscle mass in preterm infants [4]. This could result in inconsistent dosing.

Fields of Study & Subjects

Pharmaceutical studies and practices Cytomegalovirus and herpesvirus research Antibiotics Pharmacokinetics and Efficacy

Publication details

Journal / source
The Journal of Infectious Diseases
Volume
234
Issue
3
Pages
e734–e735
Publication date
24 March 2026
Language
EN